BeiGene announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has issued an opinion recommending approval for tislelizumab as monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma after prior platinum-based chemotherapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BGNE:
- BeiGene to hold an investor research and development day
- PepsiCo downgraded, Chewy upgraded: Wall Street’s top analyst calls
- Immix Biopharma second interim clinical trial data readout for IMX-110
- BeiGene initiated with a Buy at Citi
- BeiGene announces FDA acceptance of sNDA for fifth Brukinsa indication